ERBB2 and breast carcinoma: Landmark clinical trials such as DESTINY-Breast03, ASCENT, and TROPION-Breast01 have demonstrated unprecedented improvements in progression-free and overall survival, establishing ADCs as a core component of modern breast cancer treatment across HER2-positive, triple-negative, and HR+/HER2− subtypes.